Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen
复制标题
DOI：
10.1080/10428194.2023.2278026
复制
发表时间：
2023-11-08
影响因子：
2.6
通讯作者：
Zhou，Hongsheng
中科院分区：
文献类型：
--
作者：
Ou，Jiawang;Xu，Xiuli;Zhou，Hongsheng
TP53 突变 (TP53mut) 对成人急性淋巴细胞白血病 (ALL) 的预后影响仍存在争议。在此，我们确定了 TP53mut 在接受儿科方案治疗的 283 名成人 ALL 患者中的临床意义。 11.0%（31）例患者中发现TP53mut，其中青少年和青年（AYA）患者19例，非AYA患者12例。 TP53mut 患者在非 AYA 亚组中的总生存期 (OS) 和无事件生存期 (EFS) 较差 (n= 64)（3 年 OS，18.2% vs 50.9%，p= .0033；3 年 EFS，0 vs 45.3%，p= .00028）。然而，由于患者数量有限，必须谨慎对待。在 AYA 亚组 (n= 219) 中，TP53mut 不影响 OS 或 EFS（3 年 OS，60.6%vs71.0%，p= .55；3 年 EFS，52.5%vs59.6%，p= .57）。总的来说，我们的数据表明，儿科治疗方案消除了 TP53mut 对 AYA ALL 不良预后的影响。然而，在非 AYA ALL 患者中，TP53mut 仍然是与不良预后相关的潜在生物标志物。
The prognostic impact of TP53 mutations (TP53mut) in adult acute lymphoblastic leukemia (ALL) remains debatable. Herein, we determined the clinical significance of TP53mut in 283 adult ALL patients treated with a pediatric-type regimen. TP53mut were found in 11.0% (31) of patients, including 19 cases in adolescent and young adult (AYA) patients and 12 cases in non-AYA patients. Patients with TP53mut had poorer overall survival (OS) and event-free survival (EFS) in the non-AYA subgroup (n= 64) (3-year OS, 18.2% vs 50.9%,p= .0033; 3-year EFS, 0 vs 45.3%,p= .00028). however, this had to be taken cautiously due toalimited number of patients. In the AYA subgroup (n= 219), TP53mut did not impact OS or EFS (3-year OS, 60.6%vs71.0%,p= .55; 3-year EFS, 52.5%vs59.6%,p= .57). Collectively, our data reveal that the pediatric-type regimen eliminated the poor prognostic impact of TP53mut in AYA ALL. However, in non-AYA ALL patients, TP53mut remainapotential biomarker associated with poor outcomes.